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Abstract: Spices were used as food preservatives prior to the advent of refrigeration, suggesting the
possibility of effects on microbiota. Previous studies have shown prebiotic activities in animals and
in vitro, but there has not been a demonstration of prebiotic or postbiotic effects at culinary doses in
humans. In this randomized placebo-controlled study, we determined in twenty-nine healthy adults
the effects on the gut microbiota of the consumption daily of capsules containing 5 g of mixed spices at
culinary doses by comparison to a matched control group consuming a maltodextrin placebo capsule.
The 16S ribosomal RNA sequencing data were used for microbial characterization. Spice consumption
resulted in a significant reduction in Firmicutes abundance (p < 0.033) and a trend of enrichment
in Bacteroidetes (p < 0.097) compared to placebo group. Twenty-six operational taxonomic units
(OTUs) were different between the spice and placebo groups after intervention. Furthermore, there
was a significant negative correlation between fecal short-chain fatty acid propionate concentration
and Firmicutes abundance in spice intervention group (p < 0.04). The production of individual fecal
short-chain fatty acid was not significantly changed by spice consumption in this study. Mixed spices
consumption significantly modified gut microbiota, suggesting a prebiotic effect of spice consumption
at culinary doses.
Keywords: spices; gut microbiota; prebiotic effect; firmicutes; short-chain fatty acids; dietary
intervention
1. Introduction
An increasing body of evidence suggests that the gut microbiota has a profound impact on human
health. While the microbiome of a healthy individual is relatively stable, gut microbial dynamics
can be influenced by host lifestyle and dietary choices [1]. An acute change in dietary pattern from
animal-based to plant-based diet alters gut microbial populations within 24 h and then reverts to baseline
within 48 h of returning to the baseline dietary pattern [2]. Studies that involve intake of a specific
dietary component demonstrate how certain microbiota tend to respond to nutrient-specific challenges.
Protein, fats, digestible and non-digestible carbohydrates, probiotics, and dietary polyphenols all induce
shifts in the microbiome with secondary effects on host immunological and metabolic markers [1,3].
An emerging and rapidly growing scientific literature is implicating the microbiome in a number of
conditions and disorders including inflammatory bowel disease, obesity, type 2 diabetes mellitus,
cardiovascular disease, cancer, autism, mood and neurodegenerative disorders [4–8].
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The consumption of polyphenol-rich foods, including fruits and vegetables, has been reported to
reduce pathogenic Clostridia and to enrich beneficial bacteria such as Bifidobacterium and Lactobacillus
species in human studies [9,10]. In conjunction with these changes, reductions in plasma triglycerides
and C-reactive protein have been noted [9]. Dietary polyphenols have been shown to help maintain
intestinal health by preserving the gut microbial balance through the stimulation of the growth of
beneficial bacteria and the inhibition of pathogenic bacteria, exerting prebiotic-like effects.
We have previously demonstrated the effect of water extract of culinary spices, including cinnamon,
Mediterranean oregano, ginger, rosemary, black and cayenne pepper, on the growth of 33 Bifidobaterium
and Latobacillus spp., and its antimicrobial activity against 88 intestinal, pathogenic, and toxigenic
bacterial strains in an in vitro model. These spices promoted the growth of Bifidobaterium and Latobacillus
spp. Cinnamon, ginger, oregano, black pepper, and cayenne pepper showed activity against several
pathogenic Fusobaterium and Ruminococcus spp. and selected Clostridium difficile strains [11]. The present
pilot study was designed to investigate the effects of mixed spices (cinnamon, oregano, ginger, black
pepper, and cayenne pepper) at culinary doses consumed over 2 weeks in a standardized 5 g capsule
on the production of gut microbiota and short-chain fatty acids (SCFAs) in healthy subjects compared
to a placebo maltodextrin capsule in a parallel randomized controlled clinical trial.
2. Materials and Methods
2.1. Study Design and Spice Intervention
The pilot study was conducted in accordance with the guidelines of the Office of the Human
Research Protection Programs (OHRPP) of the University of California, Los Angeles. The clinical
protocol was approved by the UCLA Internal Review Board (IRB) and the study was registered at the
NIH Clinical Trial Registry (NCT03676803). A total of 66 healthy women and men aged 18 to 65 were
screened in 2017 through local advertisement. Participants with a history of gastrointestinal surgery,
diabetes mellitus, or other serious medical conditions such as chronic hepatic or renal disease, bleeding
disorder, congestive heart disease, chronic diarrhea, myocardial infarction, coronary artery bypass
graft, angioplasty within 6 months prior to screening, current diagnosis of uncontrolled hypertension
or chronic gastrointestinal disorders, bulimia, anorexia, laxative abuse, or endocrine disorders were
excluded. Participants who were consuming a high-fiber/polyphenol diet; taking any medication
or dietary supplement interfering with the absorption of polyphenols; pregnant or breastfeeding;
frequently using prebiotics, probiotics, yogurt, or fiber supplements; taking antibiotics or laxatives
within the previous 3 months; or currently using tobacco products were also excluded. Thirty-one
subjects meeting enrollment criteria were recruited and provided written informed consent before the
study began. A randomized, placebo-controlled, double-blind pilot study was conducted. Subjects
were randomized according to an algorithm modified from a previous publication [12]. The study was
divided into two periods: an initial run-in period of 1 week and an intervention period of 2 weeks.
After the run-in period, 31 subjects were randomly allocated to consume either 5 g capsules of spice
mixture containing 1 g (20%) cinnamon, 1.5 g (30%) oregano, 1.5 g (30%) ginger, 0.85 g (17%) black
pepper, and 0.15 g (3%) cayenne pepper, or 5 g capsules containing maltodextrin daily for 2 weeks.
The individual spices were purchased from local grocery stores.
At the start of study, participants received a diet instructional handout and were counseled by
a registered dietitian on compliance. During the run-in and intervention period, all participants
consumed a beige diet (low fiber < 10 g and low polyphenols < 3 servings of polyphenol rich
fruit/vegetables per day). The beige diet handout advised participants to eat foods beige in color and
rich in simple carbohydrates like white breads/bagels, crackers, granola bars, rice, macaroni/pasta,
yogurt, dairy, poultry, cereal, and bananas and to avoid foods high in polyphenols and/or fiber.
Participants were also provided with weekly checklists to track their fruit and vegetable intake
throughout the study with a limit of three servings per day. This checklist included a list of higher
fiber/polyphenol foods to avoid as well as a list of lower fiber/polyphenol fruits and vegetables they
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could consume as a part of their three servings per day, with a serving size estimation tool included.
At the baseline and final visits, participants also completed and returned 3-day food records that were
evaluated by the dietitian for compliance with the beige diet.
At baseline and at the end of 2 weeks of intervention period, body weight, body mass index
(BMI) and composition were determined. Body composition was measured using the Tanita-BC418
bioelectrical impedance analyzer (Tanita Corp., Tokyo, Japan). Height was measured without shoes
using a stadiometer (Detecto-Medic; Detecto-Scales; Brooklyn, NY, USA) and recorded to the nearest
0.1 cm. In the meantime, subjects reported on their overall well-being at baseline and at the end of two
weeks by completing the SF-36 general wellness questionnaire.
2.2. Sample Collection
Fasting blood, 24 h urine, and stool samples were collected from each participant at baseline and
at week 2 follow-up visit. Blood in EDTA was centrifuged 1500× g for 10 min at 10 ◦C and plasma
stored at −80 ◦C until analysis. Stool collection utilized Stool Collection Kit (Thermo Fisher Scientific,
Waltham, MA, USA), as per instructions, and specimen was stored on ice pack in a freezer box for up
to 24 h before delivery on ice packs to UCLA. Subjects’ self-reported stool type numbers from The
Bristol Stool Chart were recorded for assessment of stool consistency, and subjects also completed
the UCLA Digestive Disease Center Symptom Questionnaire for the assessment of gastrointestinal
symptoms (gas, bloating, diarrhea, etc.). At UCLA, the specimen was processed immediately and the
aliquots stored at −20 ◦C.
2.3. Determination of Fecal SCFA and Urinary Rosmarinic Acid
Aliquot of stool samples was diluted, acidified, and filtered, and SCFAs (acetic, propionic, butyric,
and valeric acid) were quantified by gas chromatography flame ionization detection, as previously
described [13]. SCFA standard mix was purchased from Sigma-Aldrich (St Louis, MO, USA). Urinary
free rosmarinic acid as a biochemical marker of adherence to spice supplementation was measured by
high-performance liquid chromatography according to published methods [11,14].
2.4. DNA Extraction, 16S rRNA Sequencing, and Taxonomic Assignment
DNA from stool was extracted using the MoBio power soil DNA isolation kit (MoBio Laboratories,
Carlsbad, CA, USA). The quality and quantity of the DNA was confirmed using a Nanodrop 1000
(Thermo Fisher Scientific. Sequencing was performed at MR DNA (www.mrdnalab.com, Shallowater,
TX, USA) on a MiSeq (Illumina, San Diego, CA, USA), following the manufacturer’s guidelines.
The minimum DNA concentration was 10 ng/µL. Negative controls were analyzed with the samples.
The phiX ratio was a minimum of 20%. The 16S rRNA gene V4 variable region PCR primers 515/R806
with barcode on the forward primer were used in a 28 cycle PCR using the HotStarTaq Plus Master Mix
Kit (Qiagen, Germantown, MD, USA) under the following conditions: 94 ◦C for 3 min, followed by 28
cycles of 94 ◦C for 30 s, 53 ◦C for 40 s, and 72 ◦C for 1 min, after which a final elongation step at 72 ◦C for
5 min was performed. After amplification, PCR products were checked in 2% agarose gel to determine
the success of amplification and the relative intensity of bands. Sequence data were processed using
MR DNA analysis pipeline (MR DNA). In brief, sequences were joined and depleted of barcodes,
then sequences <150 bp and sequences with ambiguous base calls were removed. Sequences were
then denoised, operational taxonomic units (OTUs) generated, and chimeras removed. OTUs were
defined by clustering at 3% divergence (97% similarity). Final OTUs were taxonomically classified
using BLASTn against a curated database derived from Greengenes 12_10 [15].
2.5. Identification of Changes in OTU Abundance Associated with Intervention
To explore the changes of microbial composition during intervention, all analyses were conducted
in R (version 3.5.2) (The R Foundation, Vienna, Austria) [16] with applied packages, including
“phyloseq” [17], “ggplot2” [18], “vegan” [19], and “DESeq2” [20]. An OTU count table, taxonomy
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classification table, related clinical and demographic data, and the OTU phylogenetic tree were
imported and analyzed as a “phyloseq” object. Measures of beta-diversity were computed using
the weighted and unweighted UniFrac distance metric using phyloseq in R. Differences in whole
communities across groups were determined by Permutational Multivariate Analysis of Variance
(PERMANOVA) using the Adonis command provided by Vegan in R. The results were visualized via
Principal Coordinate Analysis (PCoA) ordination (ggplot2).
OTUs differentially abundant between follow up and baseline visits in subjects receiving spice
and placebo interventions were identified using DESeq2 [20]. This algorithm performs normalization
using size factors estimated by the median-of-ratios method, employs an empirical Bayesian approach
to shrink dispersion, and fits the data to negative binomial models [21]. Differential abundance was
determined using the Wald test with automatic filtering of low abundance OTUs and automatic
calculation of adjusted p-values (Bonferroni correction), and the enriched OTUs were visualized using
the ggplot2 package in R. As Bonferroni correction is often considered overly conservative, an extended
set of OTUs significant at p < 0.2 was listed.
Differentially abundant OTUs between spice and placebo groups were also detected by DESeq2.
Null and test models were constructed for each OTU using DESeq. Each model includes variables
“time” (baseline and follow up) and “intervention” (placebo or spice). Differentiating the two models
was an interaction between “time” and “intervention”, which was only present in the test model.
To identify OTUs with abundance changes that occurred specifically with spice but not placebo
intervention, we used a likelihood ratio test (LRT) to test for a significant additional contribution of the
interaction between time and spice vs. placebo exposure on OTU abundance in the test model when
compared to the null model.
2.6. Statistical Analysis
Descriptive statistics, such as mean ± SEM, were used to summarize subjects’ demographic
characteristics and biochemical results. Regression was calculated using LINEST function in Microsoft
Excel 2010 (Microsoft Corporation, Redmond, WA, USA). Statistical difference of alpha diversity
(Chao1 and Shannon), fecal SCFAs, and bacterial abundance at phylum levels were evaluated between
interventions and overtime using a mixed model ANOVA, as there was a mixture of between groups
(spice and placebo) and repeated measures (baseline and follow-up) variables using IBM SPSS Statistics
version 23 (IBM, Armonk, NY, USA). Statistical significance was accepted at p ≤ 0.05.
3. Results
3.1. Subjects
Sixty-six healthy adults aged 18–65 years were screened, and 31 participants who met the
enrollment criteria were recruited, randomized, and completed the 2-week study (Figure 1). Data of
one subject from placebo group and one from spice group who did not comply with protocol was
excluded based on the result of urinary rosmarinic acid analysis. Hence the mean concentration
of rosmarinic acid in 24 h urine was 65.1 ± 63.8 µg from spice group (n = 14) and 0 ± 0 in placebo
group (n = 15). Table 1 lists subjects’ baseline characteristics of placebo group and spice intervention
group. Placebo group included 4 men and 11 women, had a mean BMI of 26.9 ± 4.5, had body fat of
30.0 ± 7.9%, and were aged 36.7 ± 13.3 years; spice intervention group included 4 men and 10 women,
had a BMI of 28.2 ± 7.0, had body fat of 32.0 ± 12.5% and were aged 34.4 ± 12.5 years. In both groups,
percent of body fat in males was lower than females. There was no statistical difference between
groups for each variable.
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After a 2-week intervention period, the body weight and percent of body fat remained unchanged 
compared to baseline for both groups. There was no significant difference in general well-being scores as 
well as Bristol stool type and frequency. Two participants in spice group reported transient bloating, 
nausea, and stomach discomfort at the beginning of supplementation. 
3.3. Microbial Composition 
Figure 1. Flowchart of study subjects. A total of 31 subjects were randomized and completed study.
Twenty-nine subjects were included in data analysis. Two subjects were excluded due to non-adherence
to protocol.
Table 1. Selected baseline characteristics of study participants.
Placebo Group Spice Group p-Value
Enrolled/randomized 15 14
Age, years 36.7 ± 13.3 34.4 ± 12.5 0.63 a
Sex
Male (N) 4 4
Female (N) 11 10 0.91 b
Race
African American (N) 1 3
White (N) 9 6
Asian (N) 3 3
Multi-Racial (N) 2 2
Other 0 1 0.57
Weight, kg 75.6 ± 16.9 76.7 ± 16.4 0.95
BMI, kg/m2 26.9 ± 4.5 28.2 ± 7.0 0.54
Body fat c (%) 30.0 ± 7.9 32.0 ± 12.5 0.63
Values are presented as mean ± SD. a For continuous data, p-value derived from t-tests. b For categorical data,
p-value derived from Chi Square distribution tests. c Body fat (%) was determined by Tanita-BC418 bioelectrical
impedance analyzer. Body mass index (BMI) was calculated by weight/height2.
3.2. Body Mass Index, Body Composition, Wellness Score, and Bristol Stool Scores
After a 2-week intervention period, the body weight and percent of body fat remained unchanged
compared to baseline for both groups. There was no significant difference in general well-being scores
as well as Bristol stool type and frequency. Two participants in spice group reported transient bloating,
nausea, and stomach discomfort at the beginning of supplementation.
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3.3. Microbial Composition
Alpha-diversity (i.e., diversity within a sample) for the spice and placebo group is shown in
Figure 2. Supplementation of spice did not significantly affect α diversity indices of richness as
measured by Chao 1 (Figure 2A) and richness and evenness as measured by Shannon index (Figure 2B).
The unweighted and weighted UniFrac distance metric were calculated and visualized via principle
coordinate analyses (PCoA) (Figure 3A,B). Neither weighted nor unweighted UniFrac distance metric
showed a distinct separation between baseline and follow-up visits in placebo or spice groups
(Figure 3A,B).
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Figure 2. Within-sample alpha-diversity of fecal of 29 subjects collected at the baseline and 2 weeks.
Calculation of the alpha-diversity for each sample for evaluating species richness and diversity by
using Chao1 (A) and Shannon (B) effective indices. The diversity of a microbial profile for a certain
index is the number of different species related to abundance and richness. PBL, placebo group at
baseline; PF, placebo group at follow up; SBL, spice group at baseline; and SF, spice group at follow up.
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The changes in relative abundance at phylum level following the 2-week spice or placebo capsule 
consumption are illustrated in Figure 4. The phylum Firmicutes showed a 6% increase in mean abundance 
in placebo group and a 10% decrease in spice group (p = 0.033) over 2 weeks. Bacteroidetes abundance 
was elevated in spice group by 19% and reduced by 14% in the placebo group (p = 0.097). The mean 
abundance of actinobateria, verrucomicrobia, proteobacteria, fusobacteria, euryarchaeota, spirochaetes, 
tenericutes, cyanobacteria, and lentisphaerae was not significantly different between groups. 
Figure 3. Beta-diversity between placebo group and spice group. Principal coordinate analysis (PCoA)
plots of all fecal samples from 29 subjects in two groups at baseline and 2 week follow up. Red circle and
green triangle represent participants in PBL and PF, blue square and purple cross represent participants
in mixed SBL and SF, respectively. (A) Unweighted UniFrac. (B) Weighted UniFrac. Axis 1, principal
coordinate 1; axis 2, principal coordinate 2. PBL, placebo group at baseline; PF, placebo group at follow
up; SBL, spice group at baseline; and SF, spice group at follow up.
The changes in rel tive abundance at phylum level following the 2-week spice or placebo
capsule consumption are illustrated in Figure 4. The phylum Firmicutes showed a 6% increase in
mean abundance in placebo group and a 10% decrease in spice group (p = 0.033) over 2 weeks.
Bacteroidetes abundance was elevated in spice group by 19% and reduced by 14% in the placebo
group (p = 0.097). The mean abundance of actinobateria, verrucomicrobia, proteobacteria, fusobacteria,
euryarchaeota, spirochaetes, tenericutes, cyanobacteria, and lentisphaerae was not significantly different
between groups.
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Figure 4. Comparison of fecal microbiota in subjects supplemented with placebo and mixed spices
capsules. Bar graph shows the relative abundance of phylum in subjects supplemented with placebo
(n = 15) or mixed spices (n = 14) at baseline and after 2 week intervention. Each color within the bar
graphs represents a phylum, with area of the color proportional to relative abundance. PBL, placebo
group at baseline; PF, placebo group at follow up; SBL, spice group at baseline; SF, spice group at follow
up. Data are means ± standard errors (SE). Significant difference in abundance between placebo and
spice group is indicated by * p < 0.05.
Twenty-six OTUs were significantly different in abundance between the groups (p < 0.02 using
DESeq2 model) after 2 week supplementation. Among them, twenty-one OTUs displayed increased
abundance and five showed reduced abundance indicated as fold change (Table 2). Changes in the
abundance of sixteen OTUs of the phylum Firmicutes, four OTUs of the Bacteroidetes, four OTUs of
the Proteobacteria, and two OTUs of the Actinobacteria were observed (p < 0.02). At family level, the
most diverse change of OTUs are within family of Lachnospiraceae (n = 4) and Ruminococcaceae (n = 4),
followed by Streptococcaceae (n = 3), Clostridiaceae (n = 2), Erysipelotrichaceae (n = 1), Lactobacillaceae
(n = 1), and Veillonellaceae (n = 1). The increasing abundance in Bacteroidaceae (n = 4) was seen in all four
Bacteroides species. The change in phylum Proteobacteria (n = 4) contained two genera and another
two classified to the class level. There was significant enrichment of Bifidobacterium animalis (24-fold
increase, p < 0.004), Bacteroidetes fraglilis (8-fold increase, p < 0.004) and Lactobacillus genus (79-fold
increase, p < 0.002), and reduction in Clostridium genus (19-fold decrease, p < 0.005). Significance with
adjusted p-values (p < 0.05 using Bonferroni correction) was found in Bacteroides (a 13-fold increase,
OTU_583656) and in Ruminococcus (a 158-fold increase, OTU_359950).
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Table 2. Log2 fold changes (FC) for operational taxonomic units (OTUs) with differential abundance
between the spice and placebo groups from baseline to 2 weeks.
Phylum/OTU No. Class, Order, Family, Genus, and Species log2 FC p padj
Actinobacteria
4426298 Actinobacteria; Bifidobacteriales; Bifidobacteriaceae;Bifidobacterium; animalis 4.578 0.004 0.496
681370 Actinobacteria; Bifidobacteriales; Bifidobacteriaceae;Bifidobacterium; pseudolongum 1.890 0.002 0.442
Bacteroidetes
583656 Bacteroidia; Bacteroidales; Bacteroidaceae; Bacteroides; 3.675 0.000 0.037
175535 Bacteroidia; Bacteroidales; Bacteroidaceae; Bacteroides; 3.138 0.014 0.839
344525 Bacteroidia; Bacteroidales; Bacteroidaceae; Bacteroides; eggerthii 3.045 0.013 0.839
351231 Bacteroidia; Bacteroidales; Bacteroidaceae; Bacteroides; fragilis 2.949 0.004 0.498
Firmicutes
679245 Bacilli; Lactobacillales; Lactobacillaceae; Lactobacillus; 6.297 0.002 0.442
1033473 Bacilli; Lactobacillales; Streptococcaceae; Streptococcus; 3.138 0.002 0.442
579608 Bacilli; Lactobacillales; Streptococcaceae; Streptococcus; 2.899 0.002 0.442
828043 Bacilli; Lactobacillales; Streptococcaceae; Streptococcus; 2.865 0.003 0.496
780650 Clostridia; Clostridiales; Clostridiaceae; 2.175 0.021 0.988
558420 Clostridia; Clostridiales; Clostridiaceae; Clostridium; −4.226 0.005 0.530
323778 Clostridia; Clostridiales; Lachnospiraceae; −3.353 0.014 0.839
176450 Clostridia; Clostridiales; Lachnospiraceae; Blautia; 2.720 0.007 0.655
589313 Clostridia; Clostridiales; Lachnospiraceae; Blautia; producta −4.178 0.005 0.568
297182 Clostridia; Clostridiales; Lachnospiraceae; Dorea; 3.264 0.020 0.988
647215 Clostridia; Clostridiales; Ruminococcaceae; Oscillospira; −3.902 0.012 0.839
359950 Clostridia; Clostridiales; Ruminococcaceae; Ruminococcus; 7.302 0.000 0.002
193336 Clostridia; Clostridiales; Ruminococcaceae; Ruminococcus; 3.631 0.009 0.777
2979308 Clostridia; Clostridiales; Ruminococcaceae; Ruminococcus; 2.520 0.009 0.777
173744 Clostridia; Clostridiales; Veillonellaceae; Megasphaera; 2.129 0.014 0.839
587530 Erysipelotrichi; Erysipelotrichales; Erysipelotrichaceae;Eubacterium; dolichum 2.819 0.015 0.839
Proteobacteria
4435655 Alphaproteobacteria;RF32; 3.483 0.010 0.778
211720 Alphaproteobacteria;RF32; 6.491 0.016 0.839
636296 Betaproteobacteria; Burkholderiales; Alcaligenaceae; Sutterella; −3.958 0.016 0.839
865469 Gammaproteobacteria; Pasteurellales; Pasteurellaceae;Haemophilus; parainfluenzae 4.238 0.021 0.988
p, p value for using DESeq set at p < 0.02; padj, adjusted p-values using Bonferroni correction.
3.4. Fecal Short Chain Fatty Acids and Correlation Analysis
Changes in each of main SCFA excretion from baseline to 2 weeks in two groups are presented
in Figure 5. The percent changes of acetate, propionate, butyrate, valerate, and the total amount
were 14.6%, 20.7%, 6.2%, 18.2%, and 14.4% for spice group and 5.4%, −1.6%, 28.1%, 27.6%, and 8.2%
for placebo group, respectively. All changes in the SCFA content in both spice and placebo group
were not statistically significant. We then evaluated correlation between each SCFA and the relative
abundance of Firmicutes and Bacteroidetes. There was a significant negative correlation between
propionate concentration and Firmicutes abundance (R= −0.391, p < 0.04) and a trend of positive
correlation between propionate concentration and Bacteroidetes abundance (R = 0.435, p < 0.07) in
spice intervention group (Table 3).
Table 3. Correlation between percent relative abundance of bacteria and SCFA concentration after 2
week spice intervention.
Acetate Propionate Butyrate Sum
R p R p R p R p
Firmicutes −0.254 0.27 −0.391 0.04 −0.210 0.28 −0.290 0.13
Bacteroidetes 0.287 0.14 0.435 0.07 0.216 0.27 −0.083 0.27
Abbreviation: regression (R); p, p value for statistical significance. Concentration of SCFA, µmol/g dry weight; Sum,
total concentration of acetate, propionate, butyrate, and valerate.
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4. Discussion
Here, we report that daily intake of 5 g of mixed spices for 2 weeks in healthy subjects resulted
in a significant reduction in the relative abundance of the phylum Firmicutes (p = 0.033), and a
trend of increasing in phylum Bacteroidetes (p = 0.097) as compared with a matched control group.
Most healthy adult microbiota are dominated by these two bacterial phyla, which together make
up about 95% of gut microbiota [22]. A significantly higher abundance of Firmicutes and a higher
Firmicutes/Bacteroidetes ratio has been frequently demonstrated in obese individuals [6,22,23], whose
gut microbiome is characterized by an increased capacity for energy harvest, inflammation, and gut
barrier disruption [24,25].
In addition to the shifts observed in Firmicutes and Bacteroidetes abundance, a number of OTUs in
the family of Bifidobateriaceae and Bacteroidaceae, as well as the family of Streptococcaceae, Lachnospiraceae,
Ruminococcacea , Veillonellaceae, and Erispelotrichac ae, were significantly alt red betw en gro ps
(Table 2). Spice interve tion significantly enh d two Bifidobacterium OTUs of the Bifidobacteriacea
family—B. animalis and B. pseudolongum—as well as one L ctobacillus OTU ompared with c ntrol group.
Bifidobacterium h s been shown to associate with the production of a number of potentially health
promoting metabolites, including short chain fatty acids, conjugat d linoleic acid, and ba teriocins [26].
The abundance of B. a imalis was reported to negatively associate with the body mass index [27].
Results from the present study are consistent with published reports in that co suming polyphenol
rich foods increases the relative abundance of Bifidobacterium and Lactobacillus and reduces pathogenic
Clostridium species [9,28,29]. Bifidobacterium and Labtobacillus are considered “healthy bacteria”, and
members of the Bifidobacterium an L ctobacillus, as well as Streptococcus, are frequently used as probiotic
strains with evident health benefits such as immune-modulation, cancer prevention, inflammation
management, and the control of diverse bacterial consortia infections [3,30,31].
We noted that the abundance of all three Ruminococcus spp. were increased. In humans,
Ruminococcus spp. were found as abundant members of a “core gut microbiome” in a majority of
humans [32]. Some Ruminococcus spp. in our gut microbiomes play an important role in helping us
degrade and convert complex polysaccharides into a variety of nutrients for their hosts [33]. The slow
digestion of these special carbohydrates has been associated with numerous health benefits such as
reversing infectious diarrhea and reducing the risk of diabetes and colon cancer [34]. Interestingly,
the Bacteroides spp., such as B. fragilis, also have the ability to recognize and metabolize plant- and
host-derived polysaccharides, and to produce polysaccharides as well [35–37]. Polysaccharide A,
e.g., synthesized by B. fragilis, can promote immunological tolerance to pathogenic species such as
Helicobacter hepaticus and protect the host from inflammation and associated colorectal cancer [35,38].
Nutrients 2019, 11, 1425 11 of 14
SCFAs constitute approximately 10% of the energy source in healthy people. These
microbial-derived products are utilized by the host and exert a range of health-promoting functions.
Butyrate is used preferentially as an energy source by the gut mucosa, is anti-inflammatory, and
protects against colorectal cancer [39], whereas propionate is largely taken up by the liver and is a good
precursor for gluconeogenesis, and promotes satiety and reduction in cholesterol liponeogenesis and
protein synthesis [40,41]. Acetate is the most predominant gut-produced SCFA in peripheral blood
and plays a role in prevention of weight gain through an anorectic effect, inflammation, and metabolic
dysregulation [42–44]. Valerate is present in substantially low amount, and research on this SCFA is
very limited. A recent study, however, showed that valerate significantly inhibited the growth of C.
difficile in vitro and in vivo, suggesting valerate can potentially be used as a safe, microorganism-free
method to treat C. difficile infection [45]. In the present work, the level of all four SCFAs was trending
higher after spice intervention but the difference did not attain statistical significance due perhaps to
the large interpersonal variations and small size of the study population. Nonetheless, our results
indicated that spice supplementation can change SCFA production.
Human studies investigating the effects of spice supplementation on gut microbiota composition
are very limited. Kang et al., reported that intake of capsaicin powder in healthy subjects increased the
Firmicutes/Bacteroidetes ratio, accompanied with increased plasma levels of glucagon-like peptide 1
and gastric inhibitory polypeptide and decreased plasma ghrelin level [46]. In animal models, Van Hul
et al., reported that cinnamon bark extract lowered fat mass gain and adipose tissue inflammation in
mice fed a high-fat diet leading to reduced liver steatosis and lower plasma nonesterified fatty acid
levels that were associated with change on the microbial composition [47]. Spices have been shown to
alter serum biochemical parameters related to inflammation or low-grade inflammation induced by
high-fat diet [47–49] and have protective effects against chronic diseases [50,51]. This evidence indicates
that spices may play important role in modulating the growth of gut microbiota and promoting
human health.
The observed lack of significant difference in microbial richness is largely attributed to the brevity
of the intervention, which is also believed to account to for the lack of change in species evenness as
well as of overall microbial composition. Another limitation of the study is that to avoid the sustained
effects [52] of spices on microbiota, our study design was a randomized placebo-controlled and not a
crossover clinical trial, therefore, there are large interpersonal variations in gut microbiota composition
and metabolite (SCFA) formation. Lastly, since this is not a controlled feeding study, dietary recall data
analyzed by a dietitian was the only method used to assess participants’ compliance with the beige
diet. Analysis of dietary data may have an impact on interpretation of the results.
5. Conclusions
The major significance of the current pilot study was that it revealed in humans for the first time
that a mixture of spices at culinary doses affects the composition of gut microbiota. These observations
also suggest but do not yet demonstrate an effect of spices on the metabolic activity of gut bacteria.
The inverse relationship between fecal propionate and the phylum Firmicutes suggests that spices may
be affecting the production of short-chain fatty acids, but our observations did not find statistically
significant changes in SCFA levels. Nonetheless, the health benefits attributed to spices throughout
ancient times may be proven in future studies of the prebiotic effects of spices in humans on glucose
metabolism, inflammation, and cognition.
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